公开(公告)号：US20230083885A1

公开(公告)日：2023-03-16

申请号：US17711961

申请日：2022-04-01

申请人： Praxis Biotech LLC

发明人： Gonzalo Andrés URETA DÍAZ ,  Brahmam PUJALA ,  Dayanand PANPATIL ,  Sebastian BERNALES ,  Sarvajit CHAKRAVARTY

IPC分类号： A61K31/4709 ,  C07K14/535 ,  C07K14/50 ,  C07D413/12 ,  C07D271/06 ,  C07D413/04 ,  C07D285/08 ,  C07D263/32 ,  C07D231/12 ,  C07D417/12 ,  C07D413/14 ,  C07D401/12 ,  A61K31/4245 ,  A61K31/538 ,  A61K31/497 ,  A61K31/433 ,  A61K31/421 ,  A61K31/415 ,  A01N43/82 ,  A01N43/84 ,  A01N43/56 ,  A01P21/00 ,  C12P21/00 ,  C12N5/071 ,  C12N15/86

摘要： The present disclosure relates generally to therapeutic agents that may be useful as modulators of Integrated Stress Response (ISR) pathway.

公开(公告)号：US20230015691A1

公开(公告)日：2023-01-19

申请号：US17779730

申请日：2020-11-26

申请人： MITSUBISHI TANABE PHARMA CORPORATION

发明人： Kohei KIKKAWA ,  Kozo OKA

IPC分类号： A61K31/538 ,  A61P1/16

摘要： The present invention aims to provide a prophylactic agent or therapeutic agent for human non-alcoholic steatohepatitis (NASH), the agent being capable of (i) reducing body weight, (ii) changing the amount of HA, the amount of PIIINP, and the amount of TIMP-1, in serum, and changing the amount of sVCAM-1 in plasma, or (iii) reducing liver stiffness. The object is achieved by a prophylactic agent or therapeutic agent for human non-alcoholic steatohepatitis (NASH), including: the 1,4-benzoxazine compound represented by Formula (I) or a pharmaceutically acceptable salt thereof as an effective component; and a pharmaceutically acceptable carrier; the agent being capable of (i) reducing body weight, (ii) changing the amount of HA, the amount of PIIINP, and the amount of TIMP-1, in serum, and changing the amount of sVCAM-1 in plasma, or (iii) reducing liver stiffness.

公开(公告)号：US20220396581A1

公开(公告)日：2022-12-15

申请号：US17228573

申请日：2021-04-12

申请人： Janssen BioPharma, Inc.

发明人： Guangyi WANG ,  Leonid BEIGELMAN ,  Anh TRUONG ,  Carmela NAPOLITANO ,  Daniele ANDREOTTI ,  Haiying HE

IPC分类号： C07D495/04 ,  A61K31/352 ,  A61K31/4196 ,  A61K31/4365 ,  C07C255/66 ,  C07D233/88 ,  C07D261/20 ,  C07D307/40 ,  C07D307/52 ,  C07D333/20 ,  C07D333/58 ,  A61K31/4025 ,  A61K31/404 ,  A61K31/427 ,  A61K31/4375 ,  A61K31/4725 ,  C07D213/50 ,  C07D233/64 ,  C07D333/68 ,  C07D401/12 ,  C07D409/06 ,  A61K31/343 ,  A61K31/382 ,  A61K31/426 ,  A61K31/4418 ,  A61K31/4545 ,  C07C251/84 ,  C07D207/335 ,  C07D215/12 ,  C07D215/42 ,  C07D233/61 ,  C07D401/04 ,  C07D409/14 ,  A61K31/277 ,  A61K31/407 ,  A61K31/423 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/497 ,  A61K31/506 ,  C07C243/34 ,  C07D209/20 ,  C07D209/86 ,  C07D233/38 ,  C07D233/60 ,  C07D277/64 ,  C07D307/81 ,  C07D405/10 ,  C07D417/04 ,  C07D417/12 ,  A61K31/165 ,  A61K31/40 ,  A61K31/4709 ,  C07C243/18 ,  C07D277/56 ,  C07D333/66 ,  C07D413/04 ,  C07D471/04 ,  C07D495/14 ,  A61K31/4427 ,  A61K31/5377 ,  C07D213/42 ,  C07D213/68 ,  C07D215/38 ,  C07D217/24 ,  C07D307/91 ,  C07D311/68 ,  C07D333/16 ,  C07D333/62 ,  C07D401/10 ,  C07D409/12 ,  A61K31/341 ,  A61K31/4164 ,  A61K31/428 ,  A61K31/444 ,  A61K31/4704 ,  A61K31/501 ,  A61K45/06 ,  C07C255/34 ,  C07D209/08 ,  C07D215/14 ,  C07D333/54 ,  C07D335/06 ,  C07D405/04 ,  C07D405/12 ,  C07D409/04 ,  C07D413/12 ,  C07D413/14 ,  A61K31/381 ,  A61K31/4155 ,  A61K31/47 ,  A61K31/538 ,  C07C251/80 ,  C07D209/14 ,  C07D213/65 ,  C07D333/50 ,  C07D333/76

摘要： Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).

公开(公告)号：US20220362174A1

公开(公告)日：2022-11-17

申请号：US17607868

申请日：2020-05-05

申请人： WEN TAN

发明人： WEN TAN

IPC分类号： A61K31/137 ,  A61K31/27 ,  A61K31/167 ,  A61K31/4704 ,  A61K31/44 ,  A61K31/538 ,  A61K31/138 ,  A61K31/55 ,  A61K31/439 ,  A61K31/5386 ,  A61K31/40 ,  A61K31/573 ,  A61P11/00

摘要： This invention disclosed new use of R-terbutaline and other R-enantiomer β2-agonists as immune-modulators for treatment of bronchia-lung inflammatory symptoms or inflammatory fibrosis remolding. This invention also disclosed new use of R-terbutaline and R-β2-agonists for reduced adverse effects related to racemic or S-enantiomer β2-agonists including airway hyper responsiveness and airway fibrosis.

公开(公告)号：US11497751B2

公开(公告)日：2022-11-15

申请号：US16964904

申请日：2019-01-25

申请人： Redx Pharma PLC

发明人： Clifford D. Jones ,  Peter Bunyard ,  Gary Pitt ,  Liam Byrne ,  Thomas Pesnot ,  Nicolas E. S. Guisot

IPC分类号： A61K31/538 ,  A61K31/4196 ,  A61K31/5377 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14

摘要： This invention relates to novel compounds and pharmaceutical compositions comprising the same. Compounds of the invention useful as modulators of Rho-associated protein kinase (ROCK), for example ROCK1 and/or ROCK2 inhibitors. Methods of treatment employing the compounds are also contemplated by the present invention. The compounds of the invention are useful in treating ROCK mediated diseases.

公开(公告)号：US11484517B2

公开(公告)日：2022-11-01

申请号：US16606235

申请日：2018-04-18

申请人： GENFIT

发明人： Robert Walczak ,  Carole Belanger ,  Vanessa Legry ,  Benoît Noel ,  Emeline Descamps ,  Guillaume Vidal ,  Mathilde Walczak ,  Isabelle Delbaere

IPC分类号： A61K31/192 ,  A61P1/16 ,  A61K31/166 ,  A61K31/198 ,  A61K31/426 ,  A61K31/437 ,  A61K31/4402 ,  A61K31/4439 ,  A61K31/506 ,  A61K31/519 ,  A61K31/52 ,  A61K31/53 ,  A61K31/538 ,  A61K31/575 ,  A61K31/662 ,  A61K31/194 ,  A61K31/438 ,  A61K31/444 ,  A61K31/5377

摘要： The present invention relates to a combination product and its use in therapy.

公开(公告)号：US20220274976A1

公开(公告)日：2022-09-01

申请号：US17685802

申请日：2022-03-03

申请人： EyePoint Pharmaceuticals, Inc.

发明人： Kevin PETERS ,  Robert SHALWITZ ,  John JANUSZ ,  Alexander SMITH

IPC分类号： C07D417/12 ,  C07D277/30 ,  C07D277/60 ,  C07D417/04 ,  C07D277/56 ,  C07D277/64 ,  C07D277/28 ,  A61K9/00 ,  A61K47/69 ,  A61K47/40 ,  A61P27/02 ,  A61P27/00 ,  C07K16/22 ,  A61K47/26 ,  A61K31/426 ,  A61K31/427 ,  A61K31/428 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/497 ,  A61K31/506 ,  A61K31/513 ,  A61K31/538 ,  A61K38/17 ,  A61K39/395

摘要： Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility are disclosed. Combination therapy with antibodies and PK/PD data are also disclosed.

公开(公告)号：US20220226335A1

公开(公告)日：2022-07-21

申请号：US17605194

申请日：2020-04-23

申请人： The Governors of the University of Alberta

发明人： Jack Jhamandas ,  Wen Fu ,  Ryoichi Kimura ,  D. Lorne Tyrrell ,  Ana Clementin ,  Kamlesh Sahu ,  Alexandr Belovodskiy ,  Mostofa Hena ,  Bing Bai ,  Appan Srinivas Kandadai ,  James A. Nieman ,  Michael Houghton

IPC分类号： A61K31/538 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/5513 ,  A61P25/28

摘要： The present disclosure provides non-peptidic heterocycle-containing amylin receptor antagonist compounds, compositions that include the subject compounds, methods for preparing and using the amylin receptor antagonists, and compositions containing the amylin receptor antagonists for treating, preventing, or ameliorating Alzheimer's disease. Aspects of the present disclosure include a method of inhibiting activity of an amylin receptor by administering to a subject in need thereof a therapeutically effective amount of an amylin receptor antagonist.

公开(公告)号：US11369760B2

公开(公告)日：2022-06-28

申请号：US15658431

申请日：2017-07-25

申请人： ANOVENT PHARMACEUTICAL (U.S.), LLC

发明人： Cai Gu Huang

IPC分类号： A61M15/00 ,  A61K31/439 ,  A61K31/167 ,  A61K31/4704 ,  A61K31/40 ,  A61K31/58 ,  A61K31/46 ,  A61K31/538 ,  A61K9/00 ,  A61M11/00 ,  A61K31/137

摘要： The invention is directed to an inhalation atomizer comprising a counter and a blocking function. Counter rotates each time the atomizer is actuated. The blocking function includes a first protrusion on the counter and a second protrusion on a lower unit of the atomizer. Once the predetermined number of actuations has been achieved, the first protrusion encounters the second protrusion and prevents further rotation of the counter so that the atomizer is blocked from further use.

公开(公告)号：US11304924B2

公开(公告)日：2022-04-19

申请号：US16779015

申请日：2020-01-31

申请人： Cardioxyl Pharmaceuticals, Inc.

发明人： Vincent Jacob Kalish ,  John Reardon ,  Frederick Arthur Brookfield ,  Stephen Martin Courtney ,  Lisa Marie Frost ,  John P. Toscano

IPC分类号： A61K31/341 ,  A61K31/18 ,  A61P9/04 ,  C07C317/14 ,  C07D307/64 ,  A61K31/255 ,  A61K31/343 ,  A61K31/381 ,  A61K31/404 ,  A61K31/42 ,  A61K31/433 ,  A61K31/4436 ,  A61K31/5377 ,  A61K31/538 ,  A61K47/12 ,  A61K47/40 ,  A61K31/222 ,  A61K31/24 ,  A61K9/00 ,  A61K9/08

摘要： The present disclosure provides nitroxyl donating pharmaceutical compositions comprising N-substituted hydroxylamine derivatives. The compositions are highly efficacious in treating cardiovascular diseases (e.g., heart failure), have a suitable toxicological profile, and are sufficiently stable for intravenous or oral administration.